Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review.

MLA

Delgado, Elías, et al. “Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review.” Diabetes Therapy, vol. 13, no. 1, July 2022, pp. 19–34. EBSCOhost, https://doi.org/10.1007/s13300-022-01278-0.

APA

Delgado, E., Jódar, E., Mezquita-Raya, P., & Moreno-Pérez, Ó. (2022). Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review. Diabetes Therapy, 13(1), 19–34. https://doi.org/10.1007/s13300-022-01278-0

Chicago

Delgado, Elías, Esteban Jódar, Pedro Mezquita-Raya, and Óscar Moreno-Pérez. 2022. “Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review.” Diabetes Therapy 13 (1): 19–34. doi:10.1007/s13300-022-01278-0.